コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 alled second-look surgeries, and intensified chemoradiotherapy.
2 (2) VPA use both at start of and still after chemoradiotherapy.
3 ould inform decision making at the outset of chemoradiotherapy.
4 ients with large tumors who are treated with chemoradiotherapy.
5 giogenic agents alone or in combination with chemoradiotherapy.
6 the routine use of induction therapy before chemoradiotherapy.
7 of esophageal cancer (EC) after neoadjuvant chemoradiotherapy.
8 age, intended surgery, and randomly assigned chemoradiotherapy.
9 cruited to the trial and started neoadjuvant chemoradiotherapy.
10 usly received platinum-based chemotherapy or chemoradiotherapy.
11 reaching clinical trials in combination with chemoradiotherapy.
12 on of physical fitness following neoadjuvant chemoradiotherapy.
13 rectal cancer routinely receive neoadjuvant chemoradiotherapy.
14 with selective rather than consistent use of chemoradiotherapy.
15 tient-specific influence of EOR and adjuvant chemoradiotherapy.
16 stratifying patients for aggressive adjuvant chemoradiotherapy.
17 -recovery study before and after neoadjuvant chemoradiotherapy.
18 were not predictive of rates of neoadjuvant chemoradiotherapy.
19 undergoing radiotherapy alone or concurrent chemoradiotherapy.
20 s lost these responses within 3 months after chemoradiotherapy.
21 umor regression and TME without preoperative chemoradiotherapy.
22 gned to CIS chemoradiotherapy versus CIS/TPZ chemoradiotherapy.
23 and 4 wk after the completion of neoadjuvant chemoradiotherapy.
24 tionship between survival, EOR, and adjuvant chemoradiotherapy.
25 e second and fourth weeks of radiotherapy or chemoradiotherapy.
26 nts with anal cancer treated with definitive chemoradiotherapy.
27 ed by radical cystoprostatectomy or combined chemoradiotherapy.
28 therapy per se is effective when compared to chemoradiotherapy.
29 nderwent (18)F-FDG and (18)F-FAZA PET before chemoradiotherapy.
30 patients in clinical trials for lung cancer chemoradiotherapy.
31 inent in the subset of patients treated with chemoradiotherapy.
32 cally advanced cervical cancer (LACC) before chemoradiotherapy.
33 int to assess clinical tumour response after chemoradiotherapy.
34 cinoma of the anus is 26 weeks from starting chemoradiotherapy.
35 isease receive perioperative chemotherapy or chemoradiotherapy.
36 NSCLC and no contraindication to concomitant chemoradiotherapy.
37 rom rectal cancer patients after neoadjuvant chemoradiotherapy.
38 utcome of an organ-preserving strategy after chemoradiotherapy.
39 sible patients should be given perioperative chemoradiotherapy.
40 omarkers for ultimate response to subsequent chemoradiotherapy.
41 ed 1-8 mo (median, 4 mo) after completion of chemoradiotherapy.
42 e randomly assigned to receive standard-dose chemoradiotherapy, 121 to high-dose chemoradiotherapy, 1
43 ard-dose chemoradiotherapy, 121 to high-dose chemoradiotherapy, 147 to standard-dose chemoradiotherap
44 ients in the capecitabine group who received chemoradiotherapy, 25 (74%) received the full protocol d
46 y assigned to receive twice-daily concurrent chemoradiotherapy (274 patients) or once-daily concurren
47 ant metastases who had received preoperative chemoradiotherapy (45 Gy in 25 daily fractions with conc
49 ated radiotherapy is, along with concomitant chemoradiotherapy, a standard of care for the treatment
52 oth gemcitabine-based and capecitabine-based chemoradiotherapy after induction chemotherapy for patie
54 motherapy to chemoradiotherapy compared with chemoradiotherapy alone for patients with head and neck
55 emoradiotherapy group and 78% (66-86) in the chemoradiotherapy alone group (hazard ratio 1.09, 95% CI
58 pare chemoradiotherapy plus panitumumab with chemoradiotherapy alone in patients with unresected, loc
59 ither docetaxel or carboplatin or concurrent chemoradiotherapy alone with two cycles of bolus cisplat
61 re treatment-related deaths in the high-dose chemoradiotherapy and cetuximab groups (radiotherapy com
63 dose chemoradiotherapy, 147 to standard-dose chemoradiotherapy and cetuximab, and 110 to high-dose ch
66 the ability to treat patients with intensive chemoradiotherapy and from potent graft-versus-leukemia
68 gical and functional outcomes of neoadjuvant chemoradiotherapy and local excision for patients with s
69 ies done at our institution (pre-neoadjuvant chemoradiotherapy and post-neoadjuvant chemoradiotherapy
70 3.5-4.8) versus 3.4 months (3.1-4.3) in the chemoradiotherapy and radiotherapy groups, respectively
71 ficacy of induction chemotherapy followed by chemoradiotherapy and surgery in patients with IIIA(N2)
74 ) T cells increased by nearly 2.5-fold after chemoradiotherapy, and ex vivo culture with PD-1-blockin
75 or patients who initially receive concurrent chemoradiotherapy, and further study in this population
77 in this study was compared with that in the chemoradiotherapy arm of the RTOG-9501 trial (Phase III
78 three timepoints: 11 weeks from the start of chemoradiotherapy (assessment 1), 18 weeks from the star
79 y (assessment 1), 18 weeks from the start of chemoradiotherapy (assessment 2), and 26 weeks from the
80 ssessment 2), and 26 weeks from the start of chemoradiotherapy (assessment 3) as well as the overall
81 t 16.5 months (95% CI, 14.5-18.5 months) and chemoradiotherapy at 15.2 months (95% CI, 13.9-17.3 mont
82 istal rectal cancer treated with neoadjuvant chemoradiotherapy at 26 American College of Surgeons Onc
85 f a pathologic complete response (pathCR) to chemoradiotherapy before surgery for esophageal cancer w
86 rcinoma (EC) who are treated with definitive chemoradiotherapy (bimodality therapy [BMT]) experience
87 d T-stage OPSCC who had completed concurrent chemoradiotherapy, bioradiotherapy, or radiotherapy with
88 otherapy were randomly assigned to receive a chemoradiotherapy boost that was risk adapted to between
90 sion-free survival and overall survival with chemoradiotherapy but at a cost of increased toxicity.
92 d busyness is associated with nonresponse to chemoradiotherapy by RECIST and with poorer prognosis.
93 with LRs occurring more than 6 months after chemoradiotherapy can undergo salvage treatment, and the
94 n before adjuvant radiotherapy or concurrent chemoradiotherapy (CCRT) could meaningfully improve 2-y
98 of the addition of induction chemotherapy to chemoradiotherapy compared with chemoradiotherapy alone
99 nificant difference in overall survival with chemoradiotherapy compared with chemotherapy alone and t
100 ined slightly lower in patients who received chemoradiotherapy compared with patients who received ra
101 with the administration of tecemotide after chemoradiotherapy compared with placebo for all patients
102 trial to investigate the benefit of adjuvant chemoradiotherapy compared with radiotherapy alone for w
103 disease vs objective response), delivery of chemoradiotherapy (concurrent vs sequential), and region
105 nger interval between the end of neoadjuvant chemoradiotherapy (CRT) and surgery is associated with a
106 e of extramural venous invasion (EMVI) after chemoradiotherapy (CRT) by both magnetic resonance imagi
108 monstrated the safety of adjuvant concurrent chemoradiotherapy (CRT) for locally advanced or incomple
109 val outcomes associated with use of adjuvant chemoradiotherapy (CRT) for patients with resected local
111 III trial was to determine whether IC before chemoradiotherapy (CRT) further improves survival compar
112 nt time points during and after preoperative chemoradiotherapy (CRT) in locally advanced rectal cance
113 h rectal carcinoma treated with preoperative chemoradiotherapy (CRT) in the CAO/ARO/AIO-94 trial.
115 ic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) may be a clinical prognostic mar
117 Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alon
119 radiotherapy (RT), or combinations of both (chemoradiotherapy, CRT) or surgery alone to identify the
120 who received preoperative gemcitabine-based chemoradiotherapy, CT-derived parameters correlated with
122 The addition of cilengitide to temozolomide chemoradiotherapy did not improve outcomes; cilengitide
123 e when assessed at 11 weeks after commencing chemoradiotherapy do in fact respond by 26 weeks, and th
124 cer treated with curative-intent neoadjuvant chemoradiotherapy do not complete postoperative chemothe
126 ing lethal tissue injury caused by intensive chemoradiotherapy during treatment of late-stage metasta
127 ticipated, our data suggest that neoadjuvant chemoradiotherapy followed by local excision might be co
128 ps undergoing SALV (n = 308) and neoadjuvant chemoradiotherapy followed by planned esophagectomy (NCR
130 nal Cancer Database who received neoadjuvant chemoradiotherapy followed by surgical resection were in
131 s with hematopoietic malignancies, involving chemoradiotherapy followed by the introduction of donor
133 al cancer who were treated with preoperative chemoradiotherapy followed by total mesorectal excision
134 duction of a clinical complete response with chemoradiotherapy, followed by observation via a watch-a
136 lticenter analysis of 87 patients treated by chemoradiotherapy for anal squamous cell carcinoma betwe
137 ants to enhance host tolerance to aggressive chemoradiotherapy for eradicating metastatic cancers.
138 support the view that nCRT according to the Chemoradiotherapy for Esophageal Cancer Followed by Surg
143 prognostic factor for patients treated with chemoradiotherapy for locally advanced non-small cell lu
147 sessment of complete clinical response after chemoradiotherapy for patients with squamous cell carcin
148 sease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment is a matter of d
149 dality to improve the outcome of neoadjuvant chemoradiotherapy for rectal cancer treatment, in suppor
150 dality to improve the outcome of neoadjuvant chemoradiotherapy for rectal cancer treatment, in suppor
152 tatements, including highlighting the use of chemoradiotherapy for select patients with MIBC and reco
153 motherapy, followed by liver resection, then chemoradiotherapy for those patients with rectal lesions
155 ia in the induction chemotherapy followed by chemoradiotherapy group (16 patients) than in the chemor
156 performed when 221 patients died (109 in the chemoradiotherapy group and 112 in the chemotherapy grou
157 20 in the induction chemotherapy followed by chemoradiotherapy group and 21 in the chemoradiotherapy
159 rol at 2 years was 61% (95% CI 47-72) in the chemoradiotherapy group and 51% (40-62) in the radiother
160 rol at 2 years was 68% (95% CI 54-78) in the chemoradiotherapy group and 61% (50-71) in the panitumum
161 60-82) in the induction therapy followed by chemoradiotherapy group and 78% (66-86) in the chemoradi
162 rolled and 150 received treatment (63 in the chemoradiotherapy group and 87 in the panitumumab plus c
163 olled, and 151 received treatment (61 in the chemoradiotherapy group and 90 in the radiotherapy plus
164 oxicity occurred in 38 (36%) patients in the chemoradiotherapy group and in 17 (16%) patients in the
165 e reported in 25 (40%) of 62 patients in the chemoradiotherapy group and in 30 (34%) of 89 patients i
166 e reported in 20 (32%) of 63 patients in the chemoradiotherapy group and in 37 (43%) of 87 patients i
167 mptom scores higher (worse symptoms) for the chemoradiotherapy group compared with radiotherapy alone
168 t 24 months, 48 (25%) of 194 patients in the chemoradiotherapy group reported severe tingling or numb
169 reatment in 309 (94%) of 327 patients in the chemoradiotherapy group versus 145 (44%) of 326 patients
170 re found in 198 (61%) of 327 patients in the chemoradiotherapy group versus 42 (13%) of 326 patients
171 re dysphagia (17 [27%] of 63 patients in the chemoradiotherapy group vs 35 [40%] of 87 in the panitum
172 inflammation (25 [40%] of 62 patients in the chemoradiotherapy group vs 37 [42%] of 89 patients in th
173 t 24 months (25 [10%] of 240 patients in the chemoradiotherapy group vs one [<1%] of 247 patients in
175 up vs 35 [40%] of 87 in the panitumumab plus chemoradiotherapy group), mucosal inflammation (15 [24%]
179 recent adherence to recommended neoadjuvant chemoradiotherapy guidelines for patients with rectal ca
180 Neoadjuvant therapy with chemotherapy or chemoradiotherapy has supplemented surgery as standard t
181 a clear role for consolidation therapy after chemoradiotherapy; however, consolidation therapy remain
182 ation radiotherapy compared with concomitant chemoradiotherapy (HR 1.22, 1.05-1.42; p=0.0098), with a
184 atment of locally advanced NSCLC, concurrent chemoradiotherapy improves local control and overall sur
185 se-intensifying temozolomide versus standard chemoradiotherapy improves overall survival (OS) or prog
186 IS chemoradiotherapy was not superior to CIS chemoradiotherapy in either PFS or OS, although definiti
187 ct pathologic response following neoadjuvant chemoradiotherapy in esophageal adenocarcinoma because m
188 ccuracy of predicting pathCR to preoperative chemoradiotherapy in esophageal cancer beyond clinical p
190 rapazamine (TPZ) to standard cisplatin (CIS) chemoradiotherapy in locally advanced cervix cancer.
191 (DW) MRI for subsequent response to radical chemoradiotherapy in locally advanced head and neck squa
192 ntibodies with radiotherapy (RT) to standard chemoradiotherapy in locoregionally advanced squamous ce
193 ntibodies with radiotherapy (RT) to standard chemoradiotherapy in locoregionally advanced squamous ce
194 nd in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (parti
195 ge disease should be treated with concurrent chemoradiotherapy in patients with good performance stat
196 etween twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-c
197 ssess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed gliob
198 a randomized controlled trial of neoadjuvant chemoradiotherapy in patients with resectable stage II-I
199 ntibody against EGFR, plus radiotherapy with chemoradiotherapy in patients with unresected, locally a
200 Here, we compared surgery with definitive chemoradiotherapy in resectable stage III disease after
202 olecularly targeted agents with radiation or chemoradiotherapy in the setting of locally advanced NSC
203 omplications associated with extensive prior chemoradiotherapy, including myocardial infarction and s
204 18)F-FLT uptake early during radiotherapy or chemoradiotherapy is a strong indicator for long-term ou
206 ally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of e
210 he patients who received previous concurrent chemoradiotherapy, median overall survival for the 538 (
212 in the resection specimen after neoadjuvant chemoradiotherapy (nCRT) and to assess its prognostic va
213 in the resection specimen after neoadjuvant chemoradiotherapy (nCRT) and to assess its prognostic va
214 urvival in patients treated with neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy for c
217 r junctional cancer who received neoadjuvant chemoradiotherapy (nCRT) followed by surgery or surgery
218 ageal cancer (EC), the impact of neoadjuvant chemoradiotherapy (NCRT) in early stages is unknown.
219 prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (EC) patie
220 ET and endoscopic assessment postneoadjuvant chemoradiotherapy (nCRT) in predicting complete patholog
221 gned to clinical trials using platinum-based chemoradiotherapy (NRG Oncology Radiation Therapy Oncolo
222 med to investigate the effect of neoadjuvant chemoradiotherapy on objectively measured in vivo muscle
224 tive biased coin design to either palliative chemoradiotherapy or radiotherapy alone for treatment of
226 Studies were eligible if patients received chemoradiotherapy or radiotherapy as the main treatment,
227 therapies with or without upfront concurrent chemoradiotherapy or radiotherapy with curative intent.
230 nts who underwent subsequent radiotherapy or chemoradiotherapy or resection, were pooled in a random-
232 In patients who received previous sequential chemoradiotherapy, overall survival did not differ betwe
236 rnofsky performance score, EOR, and adjuvant chemoradiotherapy produced a continuous, nonlinear, mult
237 on of patients who underwent radiotherapy or chemoradiotherapy ranged from 31% to 100% across studies
238 ancer who completed standardized neoadjuvant chemoradiotherapy, recruited from a large tertiary cance
239 30 mg/m(2), and should remain the preferred chemoradiotherapy regimen for LAHNSCC in the adjuvant se
240 ocarcinoma) assessed whether a postoperative chemoradiotherapy regimen that replaced FU plus LV with
241 perfractionated radiotherapy and concomitant chemoradiotherapy remains to be specifically tested.
247 ted that the addition of CRLX101 to standard chemoradiotherapy significantly increased therapeutic ef
248 atified by stage (IIIA vs IIIB), response to chemoradiotherapy (stable disease vs objective response)
252 on of patients who underwent radiotherapy or chemoradiotherapy, surgical resection after FOLFIRINOX,
253 were significantly worse in patients who had chemoradiotherapy than in patients who had radiotherapy.
254 re common in patients who received high-dose chemoradiotherapy than in those who received standard-do
255 arcinoma for patients undergoing neoadjuvant chemoradiotherapy that demonstrates that delta SUV of le
258 (2:3) by an independent vendor to open-label chemoradiotherapy (three cycles of cisplatin 100 mg/m(2)
259 f cisplatin 100 mg/m(2)) or panitumumab plus chemoradiotherapy (three cycles of intravenous panitumum
260 ell lung cancer underwent concurrent radical chemoradiotherapy to 60 Gy in 6 wk with either cisplatin
262 rognosis, and despite optimal treatment with chemoradiotherapy to the limit of tolerance, many patien
263 the idea of shifting the treatment paradigm (chemoradiotherapy, total mesorectal excision, and adjuva
265 im of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage sma
266 Gy) in 1.8 Gy fractions five times a week or chemoradiotherapy (two cycles concurrent cisplatin 50 mg
267 (2:3) by an independent vendor to open-label chemoradiotherapy (two cycles of cisplatin 100 mg/m(2) d
268 ageal junction adenocarcinoma, postoperative chemoradiotherapy using a multiagent regimen of ECF befo
270 nfortunately, disease response to concurrent chemoradiotherapy varies among patients with NPC, and ma
271 nfortunately, disease response to concurrent chemoradiotherapy varies among patients with NPC, and ma
276 wth disease-free survival from the date that chemoradiotherapy was started, and secondary endpoints w
278 %]) and neutropenia (five [11%]), and during chemoradiotherapy were dysphagia (four [9%]) and mucosit
279 t progression after receiving platinum-based chemoradiotherapy were eligible for a retrospective anal
281 these, 1,193 patients receiving neoadjuvant chemoradiotherapy were in the analysis, including 203 pa
282 taking VPA both at start of and still after chemoradiotherapy were not different from those without
283 d esophageal adenocarcinoma post-neoadjuvant chemoradiotherapy with 2 standardized PET CT studies don
284 ival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leuco
285 oice response system to receive temozolomide chemoradiotherapy with cilengitide 2000 mg intravenously
286 sponse was assessed 3 mo after completion of chemoradiotherapy with clinical examination, MRI, and (1
287 h three cycles of TPF followed by concurrent chemoradiotherapy with either docetaxel or carboplatin o
288 th 70 Gy of radiotherapy (arm A) or the same chemoradiotherapy with erlotinib 150 mg per day, startin
289 oropharyngeal cancer undergoing concomitant chemoradiotherapy with or without induction chemotherapy
294 on of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the
295 utility of reimaging rectal cancer post-CRT (chemoradiotherapy) with magnetic resonance (MR) imaging
296 han oxaliplatin at enhancing the efficacy of chemoradiotherapy, with CRLX101 and 5-fluorouracil produ
297 illance (performed 12 weeks after the end of chemoradiotherapy, with neck dissection performed only i
298 non-small-cell lung cancer who had completed chemoradiotherapy within the 4-12 week window before ran
299 Squamous cancers can be treated with primary chemoradiotherapy without surgery, depending on their re
300 d on dose intensity, assuming that high-dose chemoradiotherapy would eliminate malignant disease and
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。